Peptidify
← Back to codex

NAD+ (IV)

Aliases: Nicotinamide adenine dinucleotide · NAD IV therapy

Last verified: 2026-09-23

Research chemicalLimited evidenceSmall moleculesHigh interest

The short version

NAD+ is the molecule around which an entire 'longevity' industry is built: levels decline with age, and raising them via precursors (NMN, NR) is proven in animals. In humans, randomized trials show that NR and NMN raise NAD+ levels — but clinical outcomes (energy, metabolic markers) are modest or absent. IV 'NAD+ drips' have no controlled efficacy data. This is a classic 'biomarker yes, clinic not yet' profile.

Identity & type

Molecular type
small-molecule
Sequence / structure
— (nukleotid kofaktor)
Molecular weight
~663 Da
Formula
C21H27N7O14P2
Origin
Nicotinamide adenine dinucleotide — universal cofactor of redox reactions and sirtuin substrate.

Mechanism of action

Redox and sirtuin/PARP cofactor; IV NAD+ likely degrades before cellular uptake (precursors more efficient).

not confirmed in humans

Dosing & routes

Official / clinical context

No approved official document exists for NAD+ (IV). Any protocols mentioned are to be read as information, not as a recommendation.

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

IV protocols 250–1000 mg per session. IV sessions: users describe a strong surge of energy and mental clarity for days after; nausea during fast infusions is common. Expensive, effects vary.

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

IV sessions: users describe a strong surge of energy and mental clarity for days after; nausea during fast infusions is common. Expensive, effects vary.

Protocol — official vs community

Official / label

IV NAD+ is used clinically in addiction-detox protocols (unstandardized) and studied for infusion feasibility; oral NAD+ has poor bioavailability.

  1. 01IV: slow infusion over 2–4 h to avoid flushing/cramping

Duration: Course-based (days to weeks) in detox contexts.

IV NAD+ clinics extrapolate from detox literature to wellness — the wellness protocol is entirely commercial.

Community (anecdotal)

IV infusions (500–1,000 mg over 2–4 h) in multi-session 'loading' courses; subcutaneous NAD+ injections in newer practice.

Cycle:
Loading series then monthly 'top-ups'.
Break:
None documented.

The most expensive way to deliver a precursor whose oral analogs are unproven — the risk profile is mostly needle-related.

Human evidence

RCTs confirm NAD+ level increases; clinical benefit (energy, senescent indications) not consistently shown.

Preclinical evidence

Scant clinical literature for IV use.

Known risks

  • IV forms: nausea, chest discomfort, transient malaisecharacterized
  • Theoretical NAD+-and-tumor-growth controversy (state unknown)theoretical

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • Whether raising NAD+ in humans gives functional benefit

Frequently asked questions

References

  1. Martens C.R. et al., NR in older men (Nat Commun, 2018)
  2. Irie J. et al., NMN safety (Endocrine J, 2020)